Literature DB >> 9826475

Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions.

V Launonen1, F Stenbäck, U Puistola, R Bloigu, P Huusko, S Kytölä, A Kauppila, R Winqvist.   

Abstract

Chromosome 11q deletions are common in various malignancies, including ovarian cancer. However, the clinical significance of these genetic lesions as well as their more precise chromosomal location is largely unknown. Here we have examined epithelial ovarian cancer material from 49 patients for loss of heterozygosity (LOH) using nine microsatellite markers on 11q22.3-q25 and evaluated the effect of observed deletions with regard to different clinicopathological variables. LOH was detected in 61% of the patients. Interestingly, LOH for the D11S1340 marker locus at 11q23. 3 seemed to be associated with significantly reduced survival times (P = 0.005) and serous tumor histology (P = 0.036). LOH for D11S912 at the more distal 11q24-q25 location correlated with a higher tumor stage (P = 0.003), serous tumor histology (P = 0.015), and finding of residual tumor (P = 0.047), but not directly with survival times (P = 0.320). The majority of the analyzed tumors simultaneously displayed deletions at two distinct 11q regions, A and B, which are proximal and distal to D11S1347/NCAM (11q23.2-q23.3), respectively. Only LOH for two markers (D11S1340 and D11S912) of the B region seemed to be directly associated with a more aggressive disease course. Therefore, it appears that deletions of the ataxia telangectasia gene of the A region would not be crucial for determining the outcome of ovarian cancer. Our present results indicate that a survival factor gene in ovarian cancer would be located close to D11S1340 at 11q23.3. This corresponds well to our earlier observation in breast cancer, suggesting the involvement of a shared survival factor gene in both diseases. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826475     DOI: 10.1006/gyno.1998.5186

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  The analysis of a large Danish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 11q24.

Authors:  Laura Aviaja Rudkjøbing; Hans Eiberg; Hanne Birte Mikkelsen; Marie Louise Mølgaard Binderup; Marie Luise Bisgaard
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

3.  Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter.

Authors:  W W Noll; D R Belloni; J L Rutter; C A Storm; A R Schned; L Titus-Ernstoff; M S Ernstoff; C E Brinckerhoff
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  A common breakpoint on 11q23 in carriers of the constitutional t(11;22) translocation.

Authors:  L Edelmann; E Spiteri; N McCain; R Goldberg; R K Pandita; S Duong; J Fox; D Blumenthal; S R Lalani; L G Shaffer; B E Morrow
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

5.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

6.  The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.

Authors:  Eric S Martin; Rossano Cesari; Francesca Pentimalli; Kristine Yoder; Richard Fishel; Andrew L Himelstein; S Eric Martin; Andrew K Godwin; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

7.  Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma.

Authors:  Alicia A Tone; Carl Virtanen; Patricia A Shaw; Theodore J Brown
Journal:  Endocr Relat Cancer       Date:  2011-02-23       Impact factor: 5.678

8.  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

Authors:  Katja Lundgren; Karolina Holm; Bo Nordenskjöld; Ake Borg; Göran Landberg
Journal:  Breast Cancer Res       Date:  2008-09-29       Impact factor: 6.466

9.  Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.

Authors:  Satoshi Okada; Hitoshi Tsuda; Teruko Takarabe; Hiroyuki Yoshikawa; Yuji Taketani; Setsuo Hirohashi
Journal:  Jpn J Cancer Res       Date:  2002-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.